Question 69

Mycophenolate is subject to a Risk Evaluation and Mitigation Strategy (REMS) program because current patients should avoid becoming pregnant.

Mycophenolate is a medication that requires a REMS program due to its teratogenic effects, which can cause serious birth defects if taken during pregnancy.

A) Sertraline

Sertraline is an antidepressant that is not classified as having a REMS program related to pregnancy. While caution is advised in pregnant patients, it does not carry the same strict requirements as medications like mycophenolate, which is specifically noted for its risks in pregnancy.

B) Ondansetron

Ondansetron, used to prevent nausea and vomiting, is not subject to a REMS program for pregnancy. Although there are considerations for its use in pregnant patients, the drug does not have the same level of risk as mycophenolate, which necessitates a REMS program.

C) Montelukast

Montelukast is a medication used to manage asthma and allergies. Like ondansetron and sertraline, it does not have a REMS program related to pregnancy risks. There is no requirement to avoid pregnancy when using montelukast, making this option incorrect in the context of the question.

D) Mycophenolate

Mycophenolate is indeed subject to a REMS program due to its significant risk of causing birth defects when used during pregnancy. This program is designed to ensure that patients are adequately informed about the risks and that effective contraception is utilized during treatment.

Conclusion

Mycophenolate stands out as the only option that necessitates a REMS program due to its severe teratogenic risks, making it crucial for patients to avoid pregnancy while on this medication. The other options, while they may have considerations for use in pregnancy, do not have the same stringent regulations or risks associated with fetal development. Thus, mycophenolate is definitively the correct answer.